The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
|Slideshows|October 28, 2016
ANA 2016: Selective Neuronal Dysfunction
Author(s)Samantha J. Peterson
Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.
Advertisement
Presentations at the ANA 2016 Selective Neuronal Dysfunction and Degeneration session included studies on neuronal loss in multiple system atrophy, deep brain stimulation in early Parkinson disease, treatment of transverse myelitis with dalfampridine, and a phase I trial of MSC therapy for ALS.
Advertisement
Related to this article
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5